<p>Swiss pharmaceuticals giant Novartis said Thursday it has signed a new agreement to farm out some of its production facilities and help manufacture much-needed doses of the Pfizer-BioNTech coronavirus vaccine.</p>.<p><strong>Also read: <a href="www.deccanherald.com/national/4-more-indian-pharmaceutical-firms-expected-to-start-vaccine-production-by-oct-nov-says-mansukh-mandaviya-1015791.html" target="_blank">4 more Indian pharmaceutical firms expected to start vaccine production by Oct-Nov, says Mansukh Mandaviya</a></strong></p>.<p>Novartis has been using its factory in Stein in Switzerland to produce more than 50 million doses this year of the mRNA Covid-19 vaccine developed by German startup BioNTech and US drugmaker Pfizer.</p>.<p>The Pfizer-BioNTech vaccine is one of a handful that have been approved around the world in the global fight against the coronavirus pandemic.</p>.<p>In a statement on Thursday, Novartis said it would now "use its sterile manufacturing facilities... in Ljubljana, Slovenia, to fill at least 24 million doses in 2022."</p>.<p>The financial terms of the agreement were not disclosed.</p>.<p>Novartis said it would "take bulk mRNA active ingredient from BioNTech and fill this into vials under sterile conditions for shipment back to BioNTech for its distribution."</p>.<p><strong>Check out latest DH videos here:</strong></p>
<p>Swiss pharmaceuticals giant Novartis said Thursday it has signed a new agreement to farm out some of its production facilities and help manufacture much-needed doses of the Pfizer-BioNTech coronavirus vaccine.</p>.<p><strong>Also read: <a href="www.deccanherald.com/national/4-more-indian-pharmaceutical-firms-expected-to-start-vaccine-production-by-oct-nov-says-mansukh-mandaviya-1015791.html" target="_blank">4 more Indian pharmaceutical firms expected to start vaccine production by Oct-Nov, says Mansukh Mandaviya</a></strong></p>.<p>Novartis has been using its factory in Stein in Switzerland to produce more than 50 million doses this year of the mRNA Covid-19 vaccine developed by German startup BioNTech and US drugmaker Pfizer.</p>.<p>The Pfizer-BioNTech vaccine is one of a handful that have been approved around the world in the global fight against the coronavirus pandemic.</p>.<p>In a statement on Thursday, Novartis said it would now "use its sterile manufacturing facilities... in Ljubljana, Slovenia, to fill at least 24 million doses in 2022."</p>.<p>The financial terms of the agreement were not disclosed.</p>.<p>Novartis said it would "take bulk mRNA active ingredient from BioNTech and fill this into vials under sterile conditions for shipment back to BioNTech for its distribution."</p>.<p><strong>Check out latest DH videos here:</strong></p>